Company intelligence / Profile preview

Neurowyzr

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Neurowyzr has developed and commercialized the Digital Brain Function Screen (DBFS), a digital tool for early detection of cognitive decline. The company partners with healthcare providers to enable objective, accessible, and affordable brain health screening. Clinical validation includes comparison with established tools like MoCA and MMSE for mild cognitive impairment screening.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyDigital health tool (Digital Brain Function Screen)
Industry: Digital Health Medical Devices

Partnerships

Allium HealthcareParkway ShentonSingapore National Employers Federation

Beyond the preview

Go deeper on Neurowyzr.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurowyzr.

Explore the full profile